Skip to main content

Treatment options for multiple sclerosis patients

EDM (Early Day Motion) 1447: tabled on 04 February 2021

Tabled in the 2019-21 session.

This motion has been signed by 9 Members. It has not yet had any amendments submitted.

Motion text

That this House welcomes the Scottish Medicines Consortium’s approval of ozanimod for Scottish patients with relapsing remitting multiple sclerosis; notes that patients in Scotland will be the first in the UK to have access to this new treatment option; recognises that not all therapies work for all MS patients so it is vital to have access to all therapy options to improve patient outcomes and patient choice; looks forward to patients in the rest of the UK being afforded similar access; stresses the importance that patient and clinician perspectives are considered and incorporated into decisions on approving access to new treatments; and commends the healthcare professionals and charities that support patients with this debilitating disease, particularly during the covid-19 pandemic.